Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The P-glycoprotein multidrug transporter

O Fardel1, V Lecureur, A Guillouzo

  • 1INSERM U 49, Unité de Recherches Hépatologiques, Hôpital de Pontchaillou, Rennes, France.

General Pharmacology
|December 1, 1996
PubMed
Summary

P-glycoprotein (P-gp) is a transmembrane protein that causes multidrug resistance in cancer by pumping drugs out of cells. Researchers are exploring chemosensitizers to reverse this resistance and improve cancer treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Toward a better understanding of the etiology of systemic autoimmune diseases : should a systemic disease still be defined as a "diffuse inflammatory disease of unknown origin" in 2021? Example of crystalline silica exposure].

La Revue de medecine interne·2021
Same author

Drug-induced granulomatosis: is dupilumab the new kid on the block?

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems.

Toxicology in vitro : an international journal published in association with BIBRA·2015
Same author

Mechanisms involved in lipid accumulation and apoptosis induced by 1-nitropyrene in Hepa1c1c7 cells.

Toxicology letters·2011
Same author

Expression of p-glycoprotein in multidrug-resistant human leukemia k562 cells during erythroid-differentiation.

International journal of oncology·2011
Same author

Involvement of P-glycoprotein in an in vitro blood-brain barrier model.

International journal of oncology·2011

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • P-glycoprotein (P-gp) is a transmembrane protein responsible for ATP-dependent efflux of anticancer drugs.
  • Overexpression of P-gp in cancer cells leads to decreased intracellular drug concentrations and multidrug resistance.
  • P-gp is encoded by MDR genes, with human MDR1 and rodent mdr1/mdr3 genes implicated in drug resistance.

Purpose of the Study:

  • To provide a comprehensive overview of P-glycoprotein's role in multidrug resistance.
  • To discuss the implications of P-gp expression in various cancers and its correlation with treatment outcomes.
  • To introduce the concept and potential of chemosensitizers in overcoming P-gp-mediated drug resistance.

Main Methods:

  • Review of existing literature on P-glycoprotein structure, function, and genetics.

Related Experiment Videos

  • Analysis of P-gp expression patterns in different cancer types and normal tissues.
  • Examination of regulatory factors influencing P-gp expression.
  • Investigation of chemosensitizers as potential therapeutic agents.

    • Main Results:

    • P-gp expression is observed in a wide range of cancers, correlating with treatment failure and poor prognosis.
    • P-gp is also expressed in normal tissues like the liver and kidney.
    • P-gp function can be inhibited by chemosensitizers, which are compounds designed to reverse multidrug resistance.
    • These chemosensitizers have advanced to clinical trials.

    Conclusions:

    • P-glycoprotein is a significant factor in cancer multidrug resistance, impacting treatment efficacy.
    • Understanding P-gp regulation and expression is crucial for developing effective cancer therapies.
    • Chemosensitizers offer a promising strategy to overcome P-gp-mediated resistance and improve patient outcomes.